Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch Receives Second NIH Contract for $6.9M

NEW YORK (GenomeWeb News) – Cellectis bioresearch said today it has been awarded a second contract to provide services to the National Institutes of Health and other certain government agencies.

The multiple award, indefinite deliver/indefinite quantity contract, worth up to $6.9 million over three years, follows last week's announced $9.5 million contract with NIH. Under its terms, Cellectis bioresearch, a subsidiary of the Cellectis Group, will generate induced pluripotent stem cell lines of research grade and differentiate iPS cells toward specific tissue cell type for research use.

Based in Paris, Cellectis bioresearch provides genome customization tools and services and develops genetically customized cells adapted for drug discovery, gene function research, and protein production.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.